Skip to main content
Erschienen in: Current Atherosclerosis Reports 10/2022

30.08.2022 | Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?

verfasst von: Dixitha Anugula, Rhanderson Cardoso, Gowtham R. Grandhi, Ron Blankstein, Khurram Nasir, Mouaz Al-Mallah, Dipan J. Shah, Miguel Cainzos-Achirica

Erschienen in: Current Atherosclerosis Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The coronary artery calcium score is a guideline-endorsed aid for further risk stratification in the primary prevention of atherosclerotic cardiovascular disease. The non-contrast scan performed for detection of coronary artery calcium also gives an opportunity to visualize calcifications in the thoracic aorta and in the heart valves, at no additional cost or radiation exposure. The purpose of this review was to discuss the potential clinical value of measuring thoracic aortic calcification, aortic valve calcification, and mitral annulus calcification.

Recent Findings

After two decades of active research, all three calcifications have been extensively evaluated, across various cohorts. We discuss classic and recent studies, current knowledge gaps, and future directions in this space.

Summary

The added value of these measurements has traditionally been considered modest at best, and they are not currently discussed in relevant primary prevention guidelines in North America and Europe. However, recent studies evaluating high thoracic calcification thresholds and younger populations have further enriched this space. Specifically, some studies suggest that detection of severe thoracic aortic calcification may be helpful in further risk assessment and that detection of aortic valve calcifications may have important prognostic implications in younger individuals. Although more research is needed, particularly in larger young-to-middle-aged cohorts, future guidelines might consider including these features as risk-enhancing factors.
Literatur
5.
Zurück zum Zitat Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625.CrossRefPubMed Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143. https://​doi.​org/​10.​1161/​CIR.​0000000000000625​.CrossRefPubMed
7.
Zurück zum Zitat Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, ESC National Cardiac Societies, ESC Scientific Document Group, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.CrossRef Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, ESC National Cardiac Societies, ESC Scientific Document Group, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.CrossRef
16.
Zurück zum Zitat Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355–74. https://doi.org/10.1161/01.cir.92.5.1355.CrossRefPubMed Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355–74. https://​doi.​org/​10.​1161/​01.​cir.​92.​5.​1355.CrossRefPubMed
17.
23.
Zurück zum Zitat Sell S, Scully RE. Aging changes in the aortic and mitral valves. histologic and histochemical studies, with observations on the pathogenesis of calcific aortic stenosis and calcification of the mitral annulus. Am J Pathol. 1965;46(3):345–65.PubMedPubMedCentral Sell S, Scully RE. Aging changes in the aortic and mitral valves. histologic and histochemical studies, with observations on the pathogenesis of calcific aortic stenosis and calcification of the mitral annulus. Am J Pathol. 1965;46(3):345–65.PubMedPubMedCentral
37.•
Zurück zum Zitat Kim J, Budoff MJ, Nasir K, Wong ND, Yeboah J, Al-Mallah MH, et al. Thoracic aortic calcium, cardiovascular disease events, and all-cause mortality in asymptomatic individuals with zero coronary calcium: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2017;257:1–8. https://doi.org/10.1016/j.atherosclerosis.2016.12.012. The study focused on CAC = 0 participants from MESA, and the findings suggested that TAC > 0 was not associated with ASCVD, CHD events, and all-cause mortality adjusting for traditional risk factors.CrossRefPubMed Kim J, Budoff MJ, Nasir K, Wong ND, Yeboah J, Al-Mallah MH, et al. Thoracic aortic calcium, cardiovascular disease events, and all-cause mortality in asymptomatic individuals with zero coronary calcium: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2017;257:1–8. https://​doi.​org/​10.​1016/​j.​atherosclerosis.​2016.​12.​012. The study focused on CAC = 0 participants from MESA, and the findings suggested that TAC > 0 was not associated with ASCVD, CHD events, and all-cause mortality adjusting for traditional risk factors.CrossRefPubMed
41.••
Zurück zum Zitat Han D, Kuronuma K, Rozanski A, Budoff MJ, Miedema MD, Nasir K, et al. Implication of thoracic aortic calcification over coronary calcium score regarding the 2018 ACC/AHA Multisociety cholesterol guideline: results from the CAC Consortium. Am J Prev Cardiol. 2021;8:100232. https://doi.org/10.1016/j.ajpc.2021.100232. Findings from this study suggest that a TAC score >300 can be useful in identifying individuals at increased risk of CVD death among those with CAC = 0.CrossRefPubMedPubMedCentral Han D, Kuronuma K, Rozanski A, Budoff MJ, Miedema MD, Nasir K, et al. Implication of thoracic aortic calcification over coronary calcium score regarding the 2018 ACC/AHA Multisociety cholesterol guideline: results from the CAC Consortium. Am J Prev Cardiol. 2021;8:100232. https://​doi.​org/​10.​1016/​j.​ajpc.​2021.​100232. Findings from this study suggest that a TAC score >300 can be useful in identifying individuals at increased risk of CVD death among those with CAC = 0.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Han D, Cordoso R, Whelton S, Rozanski A, Budoff MJ, Miedema MD, et al. Prognostic significance of aortic valve calcium in relation to coronary artery calcification for long-term, cause-specific mortality: results from the CAC Consortium. Eur Heart J Cardiovasc Imaging. 2021;22(11):1257–63. https://doi.org/10.1093/ehjci/jeaa336.CrossRefPubMed Han D, Cordoso R, Whelton S, Rozanski A, Budoff MJ, Miedema MD, et al. Prognostic significance of aortic valve calcium in relation to coronary artery calcification for long-term, cause-specific mortality: results from the CAC Consortium. Eur Heart J Cardiovasc Imaging. 2021;22(11):1257–63. https://​doi.​org/​10.​1093/​ehjci/​jeaa336.CrossRefPubMed
46.•
Zurück zum Zitat Cainzos-Achirica M, Acquah I, Dardari Z, Mszar R, Greenland P, Blankstein R, et al. Long-term prognostic implications and role of further testing in adults aged ≤55 years with a coronary calcium score of zero (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2021;161:26–35. https://doi.org/10.1016/j.amjcard.2021.08.067. This study among MESA participants aged 45–55 years suggested that when present, AVC > 0 may identify a subgroup of younger adults at high ASCVD risk; however, replication in larger studies is needed as there were few participants with AVC > 0.CrossRefPubMed Cainzos-Achirica M, Acquah I, Dardari Z, Mszar R, Greenland P, Blankstein R, et al. Long-term prognostic implications and role of further testing in adults aged ≤55 years with a coronary calcium score of zero (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2021;161:26–35. https://​doi.​org/​10.​1016/​j.​amjcard.​2021.​08.​067. This study among MESA participants aged 45–55 years suggested that when present, AVC > 0 may identify a subgroup of younger adults at high ASCVD risk; however, replication in larger studies is needed as there were few participants with AVC > 0.CrossRefPubMed
Metadaten
Titel
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?
verfasst von
Dixitha Anugula
Rhanderson Cardoso
Gowtham R. Grandhi
Ron Blankstein
Khurram Nasir
Mouaz Al-Mallah
Dipan J. Shah
Miguel Cainzos-Achirica
Publikationsdatum
30.08.2022
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 10/2022
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-022-01051-5

Weitere Artikel der Ausgabe 10/2022

Current Atherosclerosis Reports 10/2022 Zur Ausgabe

Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention

Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors)

Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women

Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors)

Bempedoic Acid: for Whom and When

Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors)

Inclisiran: How Widely and When Should We Use It?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.